Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time.

[1]  C. Samama,et al.  Management of bleeding and emergency invasive procedures in patients on dabigatran: Updated guidelines from the French Working Group on Perioperative Haemostasis (GIHP) - September 2016. , 2018, Anaesthesia, critical care & pain medicine.

[2]  J. Douketis,et al.  The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale , 2017, Thrombosis and Haemostasis.

[3]  C. Samama,et al.  Perioperative management of patients on direct oral anticoagulants , 2017, Thrombosis Journal.

[4]  J. Douketis,et al.  To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment , 2016, Journal of thrombosis and haemostasis : JTH.

[5]  A. Tripodi.  To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply , 2016, Journal of thrombosis and haemostasis : JTH.

[6]  A. Tripodi,et al.  To measure or not to measure direct oral anticoagulants before surgery or invasive procedures , 2016, Journal of thrombosis and haemostasis : JTH.

[7]  S. Moll,et al.  Direct oral anticoagulant drug level testing in clinical practice: A single institution experience. , 2016, Thrombosis research.

[8]  J. Douketis,et al.  Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure , 2016, Journal of thrombosis and haemostasis : JTH.

[9]  Z. Goldberger,et al.  National Trends in Ambulatory Oral Anticoagulant Use. , 2015, The American journal of medicine.

[10]  R. Malmström,et al.  Dabigatran Concentration: Variability and Potential Bleeding Prediction In “Real–Life” Patients With Atrial Fibrillation , 2015, Basic & clinical pharmacology & toxicology.

[11]  J. Douketis,et al.  Perioperative Management of DabigatranCLINICAL PERSPECTIVE , 2015 .

[12]  P. Hjemdahl,et al.  On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation. , 2014, Thrombosis research.

[13]  D. Siegal,et al.  Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. , 2014, Journal of the American College of Cardiology.

[14]  S. Yusuf,et al.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). , 2014, Journal of the American College of Cardiology.

[15]  A. Winkler,et al.  Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross‐sectional pharmacodynamic study based on peak and trough plasma levels , 2013, Journal of thrombosis and haemostasis : JTH.

[16]  S. Chunilal,et al.  The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples , 2013, Thrombosis and Haemostasis.

[17]  P. Hjemdahl,et al.  Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma , 2013, European Journal of Clinical Pharmacology.

[18]  C. Samama,et al.  Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. , 2013, Archives of cardiovascular diseases.

[19]  N. Blais,et al.  Can Common Coagulation Assays Be Used to Estimate Dabigatran or Rivaroxaban Concentration? An Interlaboratory Comparison of 41 Hospitals in Quebec. , 2012 .

[20]  S. Yusuf,et al.  Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial , 2012, Circulation.

[21]  J. Dogné,et al.  Impact of dabigatran on a large panel of routine or specific coagulation assays , 2012, Thrombosis and Haemostasis.

[22]  M. Feuring,et al.  Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran , 2012, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[23]  T. Lindahl,et al.  Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays , 2010, Thrombosis and Haemostasis.

[24]  K. Rathgen,et al.  Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate , 2010, Clinical pharmacokinetics.

[25]  M. Feuring,et al.  Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity , 2010, Thrombosis and Haemostasis.

[26]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[27]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[28]  M. Ezekowitz,et al.  Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). , 2007, The American journal of cardiology.

[29]  K. Rathgen,et al.  Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects , 2008, Clinical pharmacokinetics.